secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001628280-24-010371
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M
----------------------------------------------------------------------

- Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.
- Net loss from continuing ops $7.7M vs $35.4M prior year; adjusted EBITDA $22.0M (+28.1%).
- Full year 2023 revenue $512.3M (flat YoY); net loss $121.2M vs $144.7M; adj. EBITDA $88.9M (+29.5%).
- Appointed Rob Claypoole as President and CEO, effective prior to Q4 close.
- FY2024 guidance: net sales $520-535M, adjusted EBITDA $89-94M, non-GAAP EPS $0.12-$0.20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/0001628280-24-010371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828024010371/bvs-20240312.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-010371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer